The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma

AIMS: The objective of this investigation was to assess the effect of aprepitant on the pharmacokinetics of high-dose melphalan used as conditioning therapy before blood stem cell transplantation in multiple myeloma. METHODS: Aprepitant (125 mg) or placebo was administered 1 h before melphalan thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Egerer, Gerlinde, Eisenlohr, Kathrin, Gronkowski, Martina, Burhenne, Juergen, Riedel, Klaus-Dieter, Mikus, Gerd
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2010
Assuntos:
Short Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3014074/
https://ncbi.nlm.nih.gov/pubmed/21175446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03792.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados